Navigation Links
AVI BioPharma Partner Cook Medical Announces Completion of Patient,Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of,Cardiovascular Disease

PORTLAND, Ore.--(BUSINESS WIRE)--Jul 10, 2007 - AVI BioPharma, Inc. (Nasdaq:AVII) announced today that its partner Cook Medical has completed target patient enrollment and released six-month follow-up data from a Phase II clinical trial known as Appraisal. The trial, currently being held in Germany, was designed to study the effect of the Neugene(R) antisense drug Resten-MP(TM), when used in conjunction with the placement of one or more bare metal stents, in the prevention of cardiovascular restenosis, the narrowing of an artery following a cardiac procedure such as angioplasty.

"We are pleased with the progress our partner Cook Medical has made with our NEUGENE in this trial," said K. Michael Forrest, interim chief executive officer of AVI. "We look forward to continuing our collaboration with Cook Medical as they work to commercialize our technology in the cardiology market."

Cook's release may be viewed on AVI's website at www.avibio.com.

About AVI BioPharma

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs and ESPRIT exon skipping technology. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI's NEUGENE-based ESPRIT technology will initially be applied to potential treatments for Duchenne muscular dystrophy. More information about AVI is available on the company's Web site at http://www.avibio.com.

About Cook Medical

Cook Medical was the first company to introduce interventional devices in the United States. Today, the company participates in all gl
'"/>




Page: 1 2

Related medicine technology :

1. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
2. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
3. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
4. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
5. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
6. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
7. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
8. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. GenoLogics Announces Bioinformatics Partnership with Illumina
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
(Date:1/15/2014)... 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... patent application concerning composition of matter, biological targets, mechanism ... cell death.  This patent application describes ... RNA molecules (VSRNAs) which interfere with the basic homeostatic ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... N.J., Nov. 3 , Third-Quarter 2009 Highlights: , ... $0.58 in third-quarter 2008 Record diluted EPS, excluding $0.06 ... $0.75, up 19.0 percent from $0.63 in third-quarter 2008 ... Specialty pharmacy revenues increased 19.2 percent to a record of ...
... , MOUNTAIN VIEW, Calif., Nov. 3 VIVUS, ... promotion of Peter Tam to president of VIVUS. In ... responsibility for VIVUS, development and business functions, including corporate ... regulatory affairs and chemistry, manufacturing and controls. Leland Wilson, ...
Cached Medicine Technology:Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 2Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 3Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 4Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 5Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 6Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 7Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 8Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 9Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 10Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 11Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 12Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 13Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 14Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 15Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 16Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 17Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 18Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 19Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 20Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 21Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 22Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 23Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 24Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 25Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 26Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 27Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 28Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 29VIVUS Announces Promotion of Peter Tam to President 2VIVUS Announces Promotion of Peter Tam to President 3
(Date:4/23/2014)... testosterone falls below normal levels are more likely to ... heart disease and type 2 diabetes. A new simple ... testing and possible treatment is described in an article ... publication from Mary Ann Liebert, Inc., publishers. The article ... Health website at http://www.liebertpub.com/jmh . ...
(Date:4/23/2014)... science, "simple and accessible detection methods that can ... resolution of a single cell inside that population ... engineer Chang Lu. , In the Royal Society ... has announced that he and his coworkers have ... location of a protein ( Chem. Sci. , ...
(Date:4/23/2014)... of probiotics, antioxidants and other nutritional compounds, more and ... is getting in on the action. But legitimate skepticism ... industry is responding with clinical research to shore up ... Chemical & Engineering News (C&EN), the weekly news ... Bomgardner, a senior editor at C&EN, writes that about ...
(Date:4/23/2014)... country as wealthy as the United States, it may come ... have access to adequate food due to lack of money ... Recent research at the University of Illinois using data from ... the seniors who are dealing with hunger are also facing ... percent of Americans over age 60 faced the threat of ...
(Date:4/23/2014)... a researcher from the Cancer Science Institute of Singapore ... identified the cancer specific stem cell which causes gastric ... new drugs for the treatment of this disease and ... by Dr Chan Shing Leng, Research Assistant Professor at ... cancer-specific variant of a cell surface protein, CD44v8-10, marks ...
Breaking Medicine News(10 mins):Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3
... ... to electronic medical records for attendees of the Michigan Osteopathic Association’s (MOA) 111th Annual ... ... Secure-24 and ATMP offered leadership and guidance about the transition from paper to electronic ...
... ... recently appointed industry leader Steve Potts as CEO. Dr. Potts brings strong business experience ... ... Biosciences LLC, a provider of digital pathology services, announced that Steven Potts ...
... 24, 2010 Genetic variation due to DNA mutation ... well as a contributing factor to disease. However, ... understood. In a report published online today in ... identified intrinsic properties of DNA that influence mutation rate, ...
... restricts the supply of blood to tumours has been developed ... vaccine slows the growth of breast cancer tumours in mice. ... a few millimetres it must be able to stimulate the ... supply of oxygen and nutrients. Drugs that prevent the growth ...
... lagging behind other developed countries, study finds , MONDAY, ... children under the age of 5 appears to be ... deaths -- than the latest mortality estimates released by ... number-crunching conducted by researchers at the Institute for Health ...
... , ... Company offers affordable expert facilitation, project management support and peer-to-peer learning opportunities to ... ... the American Academy of Family Physicians, today announced a new service offering aimed ...
Cached Medicine News:Health News:ATMP and Secure-24 Offer Physicians Leadership and Guidance for Electronic Medical Records 2Health News:ATMP and Secure-24 Offer Physicians Leadership and Guidance for Electronic Medical Records 3Health News:Digital Pathology Services Firm Flagship Biosciences Appoints New CEO 2Health News:Digital Pathology Services Firm Flagship Biosciences Appoints New CEO 3Health News:New research indicates that DNA sequence itself influences mutation rate 2Health News: A new cancer vaccine starves tumors of blood 2Health News:Global Death Rate for Children Lower Than Thought 2Health News:TransforMED Launches New Service Offering to Accelerate Medical Home Adoption in Small Practices 2Health News:TransforMED Launches New Service Offering to Accelerate Medical Home Adoption in Small Practices 3Health News:TransforMED Launches New Service Offering to Accelerate Medical Home Adoption in Small Practices 4
... better. How can one of the leading ... becoming more convenient to use in all ... TwinFix Suture Anchor with Needles combines the ... and timesaving anchor inserter and needle delivery ...
... The TACIT Threaded Anchor ... used in craniofacial and ... easy, secure tissue reattachment ... suspension. The small size ...
The Mini Anchor is an exceptionally strong, versatile anchor. This anchor comes in either a load-your-own or QUICKANCHOR format, preloaded on either 2/0 or 0 ETHIBOND EXCEL suture with swaged needles...
... FASTIN RC is a ... for rotator cuff procedures. The ... a small core to optimize ... independent suture channels to prevent ...
Medicine Products: